— Case Study —

Achieving WDA Approval and GDP Compliance for an Irish Pharmaceutical Operation

Introduction

Expanding pharmaceutical distribution activities within the European Union requires companies to comply with strict Good Distribution Practice (GDP) requirements and, where applicable, obtain a Wholesale Distribution Authorisation (WDA). Achieving regulatory approval often involves adapting existing quality systems, demonstrating supply chain control, and ensuring compliance with national regulatory expectations. This case study illustrates how we supported a pharmaceutical company in securing a WDA in Ireland by aligning its operations with EU GDP requirements and establishing the regulatory foundations needed to support its long-term growth strategy within the European market.

The Challenge

A leading pharmaceutical company sought to expand its operations within the EU market. To achieve this, obtaining a Wholesale Distribution Authorisation (WDA) in Ireland was critical for the company’s strategic growth. The company was already operating under an established pharmaceutical quality system, but adjustments were necessary to meet the specific requirements set out by the EU Good Distribution Practice (GDP) guidelines.

While the company had a solid foundation in place, its existing quality system required significant adaptation to comply with the stringent EU GDP regulations. This adaptation process was essential for securing the WDA and ensuring continued business growth within the EU. The complexity of this project necessitated detailed supply chain mapping and close collaboration between our team and the client.

Our Comprehensive Approach

Our GDP team took a leading role in managing the quality activities necessary for the WDA application. We worked in partnership with the client to adapt their quality system to align with EU GDP standards, ensuring every aspect of their supply chain and distribution processes met regulatory expectations.

Key activities included:

Supply Chain Mapping: We conducted an in-depth analysis of the company’s supply chain to ensure full compliance with GDP requirements.
System Adaptations: Adjustments to the company’s existing quality management system were made to fulfil EU-specific GDP requirements.
Close Collaboration: Our team maintained close communication with the client throughout the process to ensure timelines were met and the required documentation was in order.
Qualification of the supply chain: We conducted audits of the supply chain partners to ensure a robust vendor qualification was in place and established quality agreements with all parties.
HPRA inspection: We prepared the client for the HPRA inspection, as well as hosting and manging all the inspection activities.

Benefits

The client had a successful inspection by the Health Products Regulatory Authority (HPRA) under GDP standards, resulting in the company receiving the necessary Wholesale Distribution Authorisation (WDA).
With the WDA in hand, the company was able to proceed with its EU growth plans and meet the needs of patients across the region. Additionally, we continue to provide ongoing Responsible Person (RP) services to ensure the company maintains its regulatory compliance and operational standards.

Conclusion

The success of this project underscores our ability to navigate complex regulatory requirements and provide effective solutions that support the long-term growth of our clients within the EU pharmaceutical market.

For companies seeking WDA, GDP compliance, or Responsible Person (RP) and Responsible Person Import (RPI) services in the UK or Ireland, we offer expert guidance and support through every step of the regulatory process.

Achieve WDA Approval with Confidence

From GDP gap assessments and quality system implementation to WDA applications, inspections, and Responsible Person services, our experts help pharmaceutical companies establish and maintain compliant distribution operations across Europe.